Holen Sie sich die Stockscreener-App
163.12
0.00%
0.00
Vorhandelsmarkt:
163.12
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Cerebral Palsy Market Positioned for Significant Commercial Growth by 2036 – DelveInsight | Neurocrine Biosciences, Teva Pharma, Bundang CHA Hospital, Jazz Pharma - Barchart.com
Neurocrine presents tardive dyskinesia treatment data at conference - StreetInsider
Neurocrine Biosciences director sells $210,071 in stock - Investing.com
Neurocrine (NBIX) director sells 1,250 shares under Rule 10b5-1 plan - Stock Titan
Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients - PR Newswire
Neurocrine reports positive INGREZZA data for TD in patients with IDD - grafa.com
Neurocrine presents data on tardive dyskinesia treatment - Investing.com
Neurocrine presents data on tardive dyskinesia treatment By Investing.com - Investing.com Australia
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities - PR Newswire
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Nears Technical Breakout with Near-Perfect Score - ChartMill
Neurocrine publishes dosing guidelines for CAH treatment drug - Investing.com
Neurocrine Biosciences Inc. (NBIX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
[144] NEUROCRINE BIOSCIENCES INC SEC Filing - Stock Titan
Behavioral Patterns of NBIX and Institutional Flows - Stock Traders Daily
Does Neurocrine Biosciences’ (NBIX) Rare Disease Push Quietly Rewire Its Endocrine Risk-Reward Profile? - simplywall.st
Oppenheimer raises Neurocrine Bio stock price target on strong results - Investing.com
Neurocrine Biosciences Insider Sold Shares Worth $5,770,235, According to a Recent SEC Filing - Moomoo
Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum - Yahoo Finance
Neurocrine Biosciences(NBIX.US) Officer Sells US$5.77 Million in Common Stock - Moomoo
Baird reiterates Neurocrine Bio stock rating on acquisition potential - Investing.com
Neurocrine (NBIX) HR chief sells 36,937 shares and exercises options in pre-set plan - Stock Titan
Neurocrine (NBIX) CMO reports RSU vesting and tax share withholding - Stock Titan
RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX) - Yahoo Finance
A Look At Neurocrine Biosciences (NBIX) Valuation As New CRENESSITY Data Heads To ENDO 2026 - simplywall.st
Neurocrine to present two-year Crenessity data at ENDO 2026 - Investing.com UK
NBIX Stock Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
Neurocrine to acquire Soleno Therapeutics for $2.9 billion By Investing.com - Investing.com Australia
Neurocrine Biosciences shares jump on fresh long-term CRENESSITY data catalyst - Quiver Quantitative
NBIX Stock Draws Bullish Targets After Soleno Deal - StocksToTrade
Neurocrine Biosciences Jumps 5.8% Amid Sector-Wide Rally - AlphaStreet
Two-year CRENESSITY data track CAH hormones, growth and quality of life - Stock Titan
Goldman Sachs Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $213 - Moomoo
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Peter Lynch GARP Opportunity with Strong Growth and a PEG Ratio of 0.82 - ChartMill
NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
William Blair Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating - Moomoo
Neurocrine Biosciences CSO Jude Onyia sells $1.76m in stock - Investing.com UK
Neurocrine Biosciences chief regulatory officer sells $354,321 in stock - Investing.com UK
Neurocrine Biosciences CSO Jude Onyia sells $1.76m in stock By Investing.com - Investing.com South Africa
A Look at Neurocrine Biosciences Inc (NBIX) After 3.8% Decline -- GF Value $183.77 vs Price $154.84 - GuruFocus
Neurocrine Biosciences chief regulatory officer sells $354,321 in stock By Investing.com - Investing.com Canada
[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan
Neurocrine (NASDAQ: NBIX) CRO sells 2,261 shares after option exercise - Stock Titan
24,965-share Rule 144 sale notice for Neurocrine (NASDAQ: NBIX) - Stock Titan
Goldman Sachs resumes Neurocrine Bio stock coverage with buy rating By Investing.com - Investing.com South Africa
Goldman Sachs resumes Neurocrine Bio stock coverage with buy rating - Investing.com
Form 144: 11,000-share sale notice tied to option exercise (NBIX) - Stock Titan
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 21% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
Neurocrine Biosciences CSO Jude Onyia sells $1.71m in shares By Investing.com - Investing.com Australia
Neurocrine Biosciences CSO Jude Onyia sells $1.71m in shares - Investing.com UK
0.31%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):